Healthcare >> CEO Interviews >> October 19, 2009
Mark A. Sirgo, Pharm.D., has been President and Chief Executive Officer of BioDelivery Sciences International since July 2005. Dr. Sirgo joined the company in August 2004 as Senior Vice President of Commercialization and Corporate Development upon the acquisition of Arius Pharmaceuticals, of which Dr. Sirgo was a Co-Founder and Chief Executive Officer. Dr. Sirgo also served as BioDelivery Sciences' Executive Vice President, Corporate and Commercial Development and Chief Operating Officer. He has more than 20 years of experience in the pharmaceutical industry, including 16 years in clinical drug development, seven years in marketing, sales and business development, and five years in executive management. Prior to his involvement with Arius Pharmaceuticals, from 2003 to 2004 he spent 16 years in a variety of positions of increasing responsibility in both clinical development and marketing at Glaxo, Glaxo Wellcome and GlaxoSmithKline, including Vice President of International OTC Development and Vice President of New Product Marketing. Among other accomplishments, Dr. Sirgo was responsible for managing the development and FDA approval of Zantac 75 while at Glaxo Wellcome. From 1996 to 1999, Dr. Sirgo was Senior Vice President of Global Sales and Marketing at Pharmaceutical Product Development, Inc. Currently he serves on the board of Salix Pharmaceuticals, a specialty pharmaceutical company specializing in gastrointestinal products. Dr. Sirgo received his Bachelor of Science in Pharmacy from Ohio State University and his doctorate from the Philadelphia College of Pharmacy and Science. Profile
TWST: Why don't we start with the history of BioDelivery Sciences and how you acquired your technology?
Dr. Sirgo: BioDelivery Sciences (BDSI) was founded in 1996. It was a spinoff of the University
